FindTrial
Sign In

A Real-world, Prospective, Observational Study on GLP-1 Receptor Agonist Adjuvant Therapy During the Weight Loss Plateau Phase After Laparoscopic Sleeve Gastrectomy

A Real-world, Prospective, Observational Study on GLP-1 Receptor Agonist Adjuvant Therapy During the Weight Loss Plateau Phase After Laparoscopic Sleeve Gastrectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120885
Enrollment
Unknown
Registered
2026-03-20
Start date
2026-03-20
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Drug Adjuvant Group:None
Routine Follow-up Group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Male or female patients with obesity meeting the surgical indications of the "Guidelines for Surgical Treatment of Obesity and Metabolic Diseases in China (2024 Edition)"; 2. Aged 18-65 years; 3. Underwent Laparoscopic Sleeve Gastrectomy (LSG) at West China Hospital, Sichuan University; 4. Met the operational definition of "Weight Loss Plateau" during postoperative follow-up; 5. Voluntarily chose to use GLP-1 receptor agonists or continue routine follow-up after clinical evaluation and shared decision-making; 6. Capable of understanding and voluntarily signing the written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Regular use of weight loss medications prior to surgery; 2. History of major abdominal surgery other than laparoscopic cholecystectomy; 3. Presence of absolute contraindications to bariatric surgery (e.g., severe cardiopulmonary insufficiency, anesthesia contraindications, unstable mental illness, drug addiction); 4. Severe postoperative complications (e.g., refractory severe gastroesophageal reflux); 5. Patients who underwent revisional bariatric surgery or used non-GLP-1RA adjuvant therapies; 6. Clear contraindications to GLP-1 receptor agonists (e.g., personal or family history of medullary thyroid carcinoma, MEN2, history of pancreatitis, pregnancy or lactation); 7. History of stroke, unstable angina, acute coronary syndrome, or NYHA class III-IV heart failure within the past 12 months; 8. Incomplete follow-up data or lost to follow-up.

Design outcomes

Primary

MeasureTime frame
Percentage of Total Weight Loss (%TWL);Percentage of weight loss after adjuvant therapy;Percentage of Excess Weight Loss (%EWL);—

Secondary

MeasureTime frame
Proportion of clinically significant weight loss;Blood biochemical and hormonal profiles;Quality of Life Score (SF-36);—

Countries

China

Contacts

Public ContactChen Yi

West China Hospital of Sichuan University

toddychan@163.com+86 138 8182 3928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026